Chemotherapy News and Research

Latest Chemotherapy News and Research

Radiotherapy: First choice treatment for low-grade glioma

In a large, international, randomized trial, initial radiotherapy was compared to temozolomide chemotherapy. A statistically significant difference between the two treatment strategies was not observed for progression-free survival, although radiotherapy was numerically favored. However, molecular tumor characterization may allow the treatment approach to be personalized and one or the other treatment modality to be selected.

30 May 2013

New hope for children with multi-system LCH

A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis can achieve survival rates as high as 84 percent-a full 15 percent improvement over the previous clinical trial in this series.

30 May 2013

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

30 May 2013

Astellas submits application for marketing approval of enzalutamide for prostate cancer

Astellas Pharma Inc. and Medivation, Inc. today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.

24 May 2013

Study suggests possible way to halt cancer development in premalignant cells

Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.

24 May 2013

TSRI scientists devise new technique to find therapeutic antibodies

Scientists at The Scripps Research Institute have devised a powerful new technique for finding antibodies that have a desired biological effect. Antibodies, which can bind to billions of distinct targets, are already used in many of the world's best-selling medicines, diagnostics and laboratory reagents.

24 May 2013

New research identifies mechanism to make cancer cells respond to chemotherapy

Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University explains why some cancer cells don't respond to chemotherapy, and identifies a mechanism to rectify that.

24 May 2013

Liposomal anthracycline-based chemotherapy effective for children with leukemia: Study

Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online today in Blood, the Journal of the American Society of Hematology.

24 May 2013

Promising approach to prevent emergence of drug-resistant forms of cancer

Re-routing anti-cancer drugs to the "power plants" that make energy to keep cells alive is a promising but long-neglected approach to preventing emergence of the drug-resistant forms of cancer - source of a serious medical problem, scientists are reporting.

24 May 2013

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.

23 May 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

New drug delivery system can help treat lung cancer

Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.

23 May 2013

Obesity directly tied to several cancers

"Obesity is a major risk factor for developing cancer, roughly the equivalent of tobacco use, and both are potentially reversible. Further, obese cancer patients do worse in surgery, with radiation or on chemotherapy - worse by any measure." Karen Basen-Engquist, Ph.D., Director of MD Anderson's new Center for Energy Balance in Cancer Prevention and Survivorship and professor of Behavioral Science.

22 May 2013

Findings suggest that a prosaposin-based drug could block metastasis spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer.

22 May 2013

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.

From Pfizer, Inc. 21 May 2013

Researchers say that receiving cancer radiation therapy late in the day may minimize hair loss

Discovering that mouse hair has a circadian clock - a 24-hour cycle of growth followed by restorative repair - researchers suspect that hair loss in humans from toxic cancer radiotherapy and chemotherapy might be minimized if these treatments are given late in the day.

21 May 2013

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Cell Therapeutics, Inc. today reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.

20 May 2013

Measuring genetic diversity within tumor predicts outcomes of patients with head and neck cancer

A new measure of the heterogeneity - the variety of genetic mutations - of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer.

20 May 2013

Peripherally inserted central catheters increase risk of dangerous blood clots

Touted for safety, ease and patient convenience, peripherally inserted central catheters have become many clinicians' go-to for IV delivery of antibiotics, nutrition, chemotherapy, and other medications.

20 May 2013

New computational method may help track tumor progression, risk of relapse

In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual cells. These technologies have led to new challenges, however, as scientists now struggle with how to make sense of the resulting trove of data. Now a solution may be at hand.

20 May 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Radiotherapy: First choice treatment for low-grade glioma

New hope for children with multi-system LCH

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

Astellas submits application for marketing approval of enzalutamide for prostate cancer

Study suggests possible way to halt cancer development in premalignant cells

TSRI scientists devise new technique to find therapeutic antibodies

New research identifies mechanism to make cancer cells respond to chemotherapy

Liposomal anthracycline-based chemotherapy effective for children with leukemia: Study

Promising approach to prevent emergence of drug-resistant forms of cancer

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

New drug delivery system can help treat lung cancer

Obesity directly tied to several cancers

Findings suggest that a prosaposin-based drug could block metastasis spread

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Researchers say that receiving cancer radiation therapy late in the day may minimize hair loss

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Measuring genetic diversity within tumor predicts outcomes of patients with head and neck cancer

Peripherally inserted central catheters increase risk of dangerous blood clots

New computational method may help track tumor progression, risk of relapse

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in